NCT07063420Active, not recruiting
Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers
Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers: A Pilot Study
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
Decision Support System (Software) for multi antidiabetic drug therapy use in type 2 diabetes (T2D).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 17 Jun 2025
- Start date
- 28 Oct 2025
- Primary completion date
- 15 Nov 2026
- Lead sponsor
- Daniel Chernavvsky, MD
- Diseases
- Type 2 diabetes
- NCT number
- NCT07063420
What you commit to
- Study type: Interventional
- Planned participants: 18
- From 28 Oct 2025 to the primary completion date, 15 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently using rapid insulin for at least three months (e.g., insulin aspart, insulin lispro, insulin regular).
- Anticipated surgical, interventional procedures or prolonged periods of fasting during this study.
Other illness
- Currently being treated for a seizure disorder.
- A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol, such as but not limited to, the following examples:
- Seizure disease
- Decompensated cardiac disease
- Inpatient psychiatric treatment in the past 6 months
- Presence of a known adrenal disorder
Other
- Currently pregnant or intent to become pregnant during the trial.
Who the study is looking for
- Age ≥18.0 years old at time of consent.
- Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months.
- Hemoglobin A1c (HbA1c) ≥ 7.0%.
- Currently using an approved long-acting insulin for at least 3 months (e.g., insulin glargine, insulin degludec).
- Treated or about to be treated with multi-drug therapies for T2D.
- If using a CGM, willingness to wear an additional study CGM during the duration of the study.
- Access to the internet and willingness to upload data during the study as needed.
- If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females who self-report that they are of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Virginia Center for Diabetes Technology Coordinator of this site? Confirm its status | Charlottesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.